News

UK Biotech & Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Latest updates
Showing 121–132 of 243 stories
Funding & Grants16 Oct 2026

Microbiotica Raises £36M Series C to Take MB310 into Phase 2 for Ulcerative Colitis

Microbiotica has raised £36 million ($48 million) in the first close of a Series C round led by the British Business Bank. The funds will take MB310 into a blinded, placebo-controlled Phase 2 trial in ulcerative colitis to confirm results from the Phase 1b COMPOSER-1 study, with Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest, Seventure Partners and all Series B investors joining the round.

Funding & Grants15 Oct 2026

Silvia Bio Raises £3M Seed to Accelerate Next-Generation Biomanufacturing

Silvia Bio, a University of Sheffield spinout, has raised a £3 million seed round led by Northern Gritstone, with Parkwalk, the UK Innovation & Science Seed Fund, Wren Capital and angel investors. The company profiles mammalian cell behaviour to find manufacturing bottlenecks in antibodies and gene therapies, then develops licensable media additives to improve yield and quality. The funding moves it into dedicated lab space at the Innovation Centre in Sheffield.

Funding & Grants15 Oct 2026

OMass Therapeutics Raises $310M (£230M) Series C to Advance Small Molecule Portfolio in Endocrinology and Immunology

OMass has closed an oversubscribed $310 million (£230 million) Series C, co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with existing backers including Syncona, Oxford Science Enterprises and the British Business Bank. The funds will take lead candidate OMS1620, an MC2 receptor antagonist, through Phase 2 trials in congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, and generate first clinical data for its SLC15A4 inhibitor.

Brainomix Partners with Pulmonary Fibrosis Foundation on AI Imaging

Brainomix has partnered with the Pulmonary Fibrosis Foundation to explore how patients and caregivers understand AI-assisted CT imaging in pulmonary fibrosis care. The collaboration will examine patient perspectives on quantitative information from Brainomix's e-Lung platform and how it might support conversations with clinicians about disease progression and treatment. It is an exploratory research partnership, not a report of clinical efficacy or regulatory approval.

Funding & Grants14 Oct 2026

HydRegen Raises $8M (£6M) First Close of Series A to Bring Biocatalysis to Industrial Chemical Manufacturing

HydRegen has closed the first tranche of its Series A at $8 million (£6 million), led by Genoa Ventures with Clean Growth Fund and First Imagine! Ventures. The Oxford company makes hydrogenase enzymes by fermentation and formulates them into catalysts to replace precious-metal catalysts in hydrogenation reactions. The funds will expand work with pharmaceutical and specialty chemical customers and take the platform into higher-volume markets.

Aptamer Group Grows FY26 Revenue 28% to £1.5M and Signs First Optimer Licensing Deals

Aptamer Group has reported full-year revenue of £1.5 million, up 28%, with its sales pipeline rising to £7.0 million after year-end and its adjusted EBITDA loss widening slightly to £2.3 million. The company signed its first royalty-bearing licences for its enzyme-modulating Optimer technology, with Twist Bioscience and Alphazyme, and says cash of £4.4 million funds it into 2028.